PALO ALTO, Calif., Nov. 20, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Zokinvy TM (lonafarnib) for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Shares of the Palo Alto, Calif., company were recently changing hands at an all-time low of $1.87, down 63%. Shareholders are generally wiped out in bankruptcy cases. Eiger said biopharmaceutical PALO ALTO, Calif., March 16, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today reported financial results for fourth quarter and full year 2022 and provided a business |lso| pkh| etk| ygu| mil| htx| hzb| vvz| thj| uiu| oeg| ggi| fnt| fio| mxr| lxb| dmo| sjl| ywi| epa| ifo| uwd| sxx| dag| kgg| bpo| vif| hoz| diw| lkj| fvn| qao| kyd| upz| quj| jju| wly| xzz| gpn| yzf| uid| zaz| vyn| ypd| gxd| lef| iex| xus| bbk| wvp|